BioFund · Europe

The science was
born here.
The network grows from here.

BioFund's research platforms were built in Europe — in Hungarian laboratories, in Austrian legal structures, in a decade of science that chose rigour over speed. The European Constellation is how we extend that work to the researchers, clinicians, and institutions whose missions align with ours.

Not a programme you apply to. A network you are invited into.

Our home territory

Everything we have built was built here. The first conversations we seek are with the people closest to that science.

BioFund was founded by seven families with a single conviction: that cancer is a problem science can solve, when the right people work on it together without an exit in view. Our research platforms were built, step by step, in European laboratories, by European scientists. Biosimilars engineered and validated in Szeged. Ultra-fine particle processing developed in Győr. A decade of OneHealth science conducted in close collaboration with university partners across the continent. The legal home is Vienna. The science is Hungarian, European, and reaching outward — into companion animal clinics, cancer centres, and research institutes that share the same long-term commitment.

We are an impact investor, not a donor. We commit our platforms first. As a collaboration proves itself, we look to build toward shared investment. Mission alignment is the entry point. Shared commitment is where serious work begins.

What we bring to a collaboration

We invest our platforms where the science is real.

Five platforms built for our own research, now opening to mission-aligned partners across Europe. Each collaboration begins with one — the specific one that fits your programme. The right partner gets access.

01

Novel proteins & biosimilars

We produce novel proteins and biosimilars for our own oncology and OneHealth research, held in a growing Master Cell Bank. Our anti-PD-L1 biosimilar is already in active use by research collaborators. When a programme needs a protein we already carry, access comes through a jointly structured project — research-grade, EMA-pathway-aware, without procurement delays.

In practice A research team at a European cancer centre needed a specific checkpoint inhibitor reference protein. We had produced it for our own work. We opened access through a joint project. Their programme moved forward — months ahead of any commercial alternative.
02

Cell line engineering

When a researcher has a molecule with real therapeutic potential and the biology is fighting back — expression unstable, yield insufficient — we engineer a stable, high-yield cell line around their molecule. The discovery stays entirely theirs. We solve the biology problem that was blocking it. Our cell line engineering is conducted at our Szeged facility, with full analytical validation by our in-house team.

In practice A researcher had a promising therapeutic candidate that would not express at the yield the work required. We built a stable cell line around it. The science that had been stalling for months began to move.
03

Animal health & OneHealth

Companion animals develop the same cancers humans do — spontaneously, in real bodies, with owners who want treatment now. We work with veterinary researchers and oncology clinics whose patients need care today. The clinical data those studies generate shortens the road to human therapeutics. One act of medicine, two beneficiaries. European veterinary medicine is among the finest in the world. We want to work inside it.

In practice Our lead therapeutic asset is entering companion animal trials first — generating real-world clinical data in a fraction of the time a conventional human-first pathway would require, while helping animals that need treatment now.
04

UFP500 — bioactive processing

We built the UFP500 platform for our own prevention research — ultra-fine particle processing that unlocks the bioactive potential of plant, marine, and agricultural materials, with documented bioavailability enhancement. Europe's botanical, marine, and agri-food heritage is extraordinary. The Mediterranean, the Nordic coastline, the Alpine meadow — each holds compounds that science has not fully mapped. We find the materials, process them through UFP500, and build the research around what we create. Co-development from the first conversation.

In practice A marine processing operation was discarding a bioactive-rich waste stream — headed for landfill. Processed through UFP500, it became a validated research ingredient. Prevention science and circular economy, in one project.
05

AI-guided bioactive discovery

We built micronutri.ai for our own search for compounds that protect cells before disease takes hold. Curing cancer is one half of the mission. Making sure fewer people need to be cured is the other half. If you have a discovery problem where that intelligence layer helps — a compound class, a target pathway, a prevention hypothesis — we work on it with you as a co-research project.

In practice micronutri.ai grew from our own prevention research — mapping the bioactive landscape to find what the science predicts will matter. The platform is open to partners whose work shares that upstream ambition.
06

Your collaboration
begins here.

The constellation is open.

EU research frameworks

BioFund holds private company status across European jurisdictions and participates in collaborative research as an industry partner. Where your work is supported by Horizon Europe, ERC, or national research council funding, BioFund works alongside that structure — contributing platforms, expertise, and co-investment as the project demands. We are accustomed to the cadence and governance of European institutional science.

How we work

Considered. Collaborative. Permanent.

i

We identify

Through our own network, through conference encounters, through a colleague who knows the right person. The first signal is usually a piece of science we find compelling — or a name that keeps appearing in the right contexts.

ii

We meet — properly

One conversation, in person where possible. We listen more than we present. The question we are trying to answer is whether the work is real and the fit is genuine. When it is, we say so. When it isn't, we say that too, and we don't waste your time.

iii

We begin with one thing

One platform, matched to one specific challenge in your programme. A real project, specific enough to start now, small enough to move quickly. We commit our platform first. IP terms are clear from day one: your discoveries stay yours.

iv

We grow the Constellation

Good work introduces the next collaborator. The network grows the way serious scientific communities always have — through results, through trust, and through the people already inside it.

If your science shares the mission, there is a place for it in the Constellation.

Start a conversation Tell us what you're working on. The right conversations find their way.
"Seven families.
One mission.
No exit."
BioFund is a fully independent Family Office with no external investors and no exit timeline. Partnership decisions are grounded entirely in mission alignment.